IMPLANTS FOR LOCALIZED DRUG DELIVERY AND METHODS OF USE THEREOF
FIG16, panels A and B, is a collection of graphs showing the measured activity of fulvestrant eluted into media from a fulvestrant-loaded silastic® tubing, according to embodiments of the present disclosure
FIG16, panels A-B: Silastic® tubing (9 cm) was loaded with 0.68 mg fulvestrant and incubated in 5 mL medium at 37°C for the indicated time (Panel A) or harvested every 24 hours and replenished with fresh and replenished with fresh medium (Panel B). The medium was then used to culture MCF7 cells for 72 h, and the cells were assayed for proliferation by MTS assay (Panel A) and harvested for protein and western blotted for ER and PR expression (Panel B). Inset in Panel B demonstrates sufficient fulvestrant release to inhibit ER and PR expression for at least 28 days. As a positive control, MCF7 cells were treated directly with 100 nM fulvestrant (last bar in Panel A), a concentration sufficient to down regulate ER expression and arrest cell growth.
graphs
28
day
5
containing
30
including totaling
12
beyond
1
implant
4
scaffold
2
silicone tubing
0
including
10
including
21
central switchback
3
U.S. Pat. Nos.
32
target tissue
['1. An implant for delivering an active agent to a target tissue, the implant comprising: a biocompatible tubing comprising a wall; and an active agent loaded in the tubing, wherein the wall is permeable to the active agent thereby delivering the active agent to the target tissue when the implant is implanted.', '4. The implant of any one of claims 1-3, wherein the tubing is silicone tubing.']